Official Title
Cardiovascular Disease, Cardiovascular Risk Factors, Treatments and Severe COVID-19 Outcomes. A Nationwide Registry-based Case-Control Study
Brief Summary

In this study we cross-reference several nationwide high-quality Swedish registers in order to study risk factors for severe Covid-19 outcomes.

Detailed Description

In this nationwide, case-control study we cross-reference several detailed, high-quality
Swedish registers in order to study risk factors associated with severe Covid-19 as well as
different disease outcomes, with a focus on cardiovascular disease, chronic kidney disease,
different treatments and socioeconomic factors. Cases are identified through the Swedish
intensive care register (SIR) and controls through the Swedish population register (RTB).
Further information on the study participants is gathered by linkage to registers on:
prescribed drugs; history of in- and outpatient care; income, education and migration.
Follow-up data such as future hospitalization and mortality will be gathered prospectively.

Active, not recruiting
COVID-19

Other: Hypertension

Exposure : Any registered diagnosis of I10 within 15 years or a registered pick-up of a prescription of antihypertensive treatment (ATC C02CA, C02DB02, C03, C07, C08, C09) within one year before index date in the Swedish prescribed drug register (exluding those with a registered diagnosis of other indications for betablocker (heart failure, atrial fibrillation) or ACE-inhibitor, ARB(heart failure) ) Exposures will be compared between cases and controls and between cases with different outcomes and controls

Other: Diabetes type 2

Exposure: Any registered diagnosis of E11 within 15 years or a registered pick-up of a prescription with any antidiabetic treatment (ATC A10) within one year before index date in the Swedish prescribed drug register.
Exposures will be compared between cases and controls and between cases with different outcomes and controls

Other: Obesity

Exposure: Diagnosis ICD E66 within 15 years before index date Exposures will be compared between cases and controls and between cases with different outcomes and controls

Drug: Antihypertensive Agents

Pick up of a prescription of C02CA, C02DB02, C03, C07, C08, C09 registered in the Swedish prescribed drug register within 6 month before index date.
Exposures will be studied separately for each antihypertensive class and compared between cases and controls and between cases with different outcomes and controls

Drug: Statins (Cardiovascular Agents)

Pick up of a prescription of C10AA registered in the Swedish prescribed drug register within 6 month before index date.

Other: Chronic kidney disease

Exposure: Diagnosis ICD N18 within 15 years before index date Exposures will be compared between cases and controls and between cases with different outcomes (mechanical ventilation, continuous renal replacement therapy mortality) and controls. Exposures will thereafter be compared in subgroups by BMI at ICU-admission and in subgroups matched by history of type 2 diabetes.

Eligibility Criteria

Inclusion Criteria:

- Cases: Admitted to intensive care unit in Sweden and registered admission in the
Swedish intensive care register (SIR) with a main diagnosis of Covid-19 confirmed by
laboratory testing (ICD10: U07.1). (cases)

- Control subjects matched for age, gender,residency: For each case 10 controls matched
for age, gender and district of residence will be identified by Statistics Sweden
(SCB) in the Swedish population register (RTB).

- Control subjects matched for age and gender: For each case 5 controls matched for age
and gender will be identified by by Statistics Sweden (SCB) in the Swedish population
register (RTB).

Exclusion Criteria:

- No valid Swedish personal identity number (PIN)

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Sweden
Locations

Södersjukhuset
Stockholm, Sweden

Karolinska Institutet
NCT Number
MeSH Terms
COVID-19
Antihypertensive Agents